Cyxone’s executive management team consists of experienced experts with solid knowledge in the fields of drug development, business development and financing in innovative biotech companies.
CEO
Born 1952. CEO since 2024.
Kjell Stenberg holds a PhD in Medical Science from Karolinska Institute in Stockholm. For 25 years, Kjell held various management roles in AstraZeneca R&D as well as Director Global Licensing within the neurology therapy area. During the past 24 years, Kjell has co-founded and led biotech companies such as Combio A/S, ACQ Med AB, BioMS Medical Corp., Accequa AB, Aptahem AB, Cyxone AB and Pepdura AB. Furthermore, he has been active at the board of the biotech companies Galecto Biotech AB, Novation Pharmaceuticals Inc, Notify Therapeutics A/S, PCI Biotech Holding ASA. Kjell has also been acting partner in the investment fund Medwell Capital Corp. In Canada and as financial advisort at Nodes Advisors in Switzerland.
He has also been a member of the independent evaluation group for Eurostars.
BioMS Medical was awarded with “License Deal of the Year” by the Scrips organization for the partner deal with Eli Lilly for the MS drug candidate “dirucotide”.
Kjell Stenberg owns 8,252,076 shares in Cyxone through ABBMO Holding AB
Interim CFO
Born 1982. Interim CFO since 2024.
Henrik Hang holds a B.Sc. in Business administration with a specialization in Finance Management. He has extensive experience as CFO in several international listed companies on Nasdaq First North Growth Market. He has previously held several CFO positions in the pharmaceutical industry and has a major interest in working with growth companies.
No shares
CFO - On leave
Born 1992. CFO since 2023.
Malin has studied Business and Administration program at Lund University with a focus on Business Law and Organization and Leadership. She has several years of experience as Controller and office Manager in public biotech companies such as Gabather AB.
No shares